Improved diagnostic accuracy for neuroendocrine neoplasms using two chromogranin A assays

Clinical Endocrinology

Volumn 76, Issue 6, 2012, Pages 831-836

  Ramachandran, Radha ^a,b   Bech, Paul ^b   Murphy, Kevin G ^b   Dhillo, Waljit S ^a,b   Meeran, Karim M ^a,b   Chapman, Richard S ^a   Caplin, Martyn ^c   Ghatei, Mohammed A ^b   Bloom, Stephen R ^a,b   Martin, Niamh M ^a,b  

^a IMPERIAL COLLEGE HEALTHCARE NHS TRUST   (United Kingdom)

^b IMPERIAL COLLEGE LONDON   (United Kingdom)

^c ROYAL FREE HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CHROMOGRANIN A; EPITOPE;

ARTICLE; CANCER DIAGNOSIS; CONTROLLED STUDY; DIAGNOSTIC ACCURACY; DIAGNOSTIC PROCEDURES; HUMAN; MAJOR CLINICAL STUDY; NEUROENDOCRINE CANCER; NEUROENDOCRINE DISEASE; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; RADIOIMMUNOASSAY;

ADULT; AGED; AGED, 80 AND OVER; CHROMOGRANIN A; FEMALE; HUMANS; LOGISTIC MODELS; MALE; MIDDLE AGED; NEUROENDOCRINE TUMORS; RADIOIMMUNOASSAY; TUMOR MARKERS, BIOLOGICAL; YOUNG ADULT;

EID: 84860151308     PISSN: 03000664     EISSN: 13652265     Source Type: Journal    
DOI: 10.1111/j.1365-2265.2011.04319.x     Document Type: Article

References (23)

1. Hemminki, K., &, Li, X., (2001) Incidence trends and risk factors of carcinoid tumors: a nationwide epidemiologic study from Sweden. Cancer 92, 2204-2210.
2. Lawrence, B., Gustafsson, B.I., Chan, A., et al. (2011) The epidemiology of gastroenteropancreatic neuroendocrine tumors. Endocrinology & Metabolism Clinics of North America 40, 1-18.
3. Modlin, I.M., Gustafsson, B.I., Moss, S.F., et al. (2010) Chromogranin A-biological function and clinical utility in neuro endocrine tumor disease. Annals of Surgical Oncology 17, 2427-2443.
4. Nobels, F.R., Kwekkeboom, D.J., Bouillon, R., et al. (1998) Chromogranin A: its clinical value as marker of neuroendocrine tumours. European Journal of Clinical Investigation 28, 431-440.
5. O'Toole, D., Grossman, A., Gross, D., et al. (2009) ENETS consensus guidelines for the standards of care in neuroendocrine tumors: biochemical markers. Neuroendocrinology 90, 194-202.
6. Lawrence, B., Gustafsson, B.I., Kidd, M., et al. (2011) The clinical relevance of Chromogranin A as a biomarker for gastroenteropancreatic neuroendocrine tumors. Endocrinology & Metabolism Clinics of North America 40, 111-134.
7. Blaschko, H., Comline, R.S., Schneider, F.H., et al. (1967) Secretion of a chromaffin granule protein, chromogranin, from the adrenal gland after splanchnic stimulation. Nature 215, 58-59.
8. Koshimizu, H., Kim, T., Cawley, N.X., et al. (2010) Chromogranin A: a new proposal for trafficking, processing and induction of granule biogenesis. Regulatory Peptides 160, 153-159.
9. Stridsberg, M., Eriksson, B., Oberg, K., et al. (2003) A comparison between three commercial kits for chromogranin A measurements. Journal of Endocrinology 177, 337-341.
10. Portela-Gomes, G.M., Grimelius, L., &, Stridsberg, M., (2010) Immunohistochemical and biochemical studies with region-specific antibodies to chromogranins A and B and secretogranins II and III in neuroendocrine tumors. Cellular and Molecular Neurobiology 30, 1147-1153.
11. Bech, P., Winstanley, V., Murphy, K.G., et al. (2008) Elevated cocaine- and amphetamine-regulated transcript immunoreactivity in the circulation of patients with neuroendocrine malignancy. Journal of Clinical Endocrinology and Metabolism 93, 1246-1253.
12. DeLong, E.R., DeLong, D.M., &, Clarke-Pearson, D.L., (1988) Comparing the areas under two or more correlated receiver operating characteristic curves: a nonparametric approach. Biometrics 44, 837-845.
13. Harris, E.K., &, DeMets, D.L., (1972) Estimation of normal ranges and cumulative proportions by transforming observed distributions to gaussian form. Clinical Chemistry 18, 605-612.
14. de Herder, W.W., (2007) Biochemistry of neuroendocrine tumours. Best Practice and Research Clinical Endocrinology and Metabolism. 21, 33-41.
15. Ardill, J.E.S., (2008) Circulating markers for endocrine tumours of the gastroenteropancreatic tract. Annals of Clinical Biochemistry 45, 539-559.
16. Mori, M., Mimori, K., Kamakura, T., et al. (1995) Chromogranin positive cells in colorectal carcinoma and transitional mucosa. Journal of Clinical Pathology 48, 754-758.
17. Hsiao, R.J., Mezger, M.S., &, O'Connor, D.T., (1990) Chromogranin A in uremia: progressive retention of immunoreactive fragments. Kidney International 37, 955-964.
18. Massironi, S., Fraquelli, M., Paggi, S., et al. (2009) Chromogranin A levels in chronic liver disease and hepatocellular carcinoma. Digestive Liver Disease 41, 31-35.
19. Stridsberg, M., &, Husebye, E., (1997) Chromogranin A and chromogranin B are sensitive circulating markers for phaeochromocytoma. European Journal of Endocrinology 136, 67-73.
20. Syversen, U., Opsjon, S.L., Stridsberg, M., et al. (1996) Chromogranin A and pancreastatin-like immunoreactivity in normal pregnancies. Journal of Clinical Endocrinology and Metabolism 81, 4470-4475.
21. Rozansky, D.J., Wu, H., Tang, K., et al. (1994) Glucocorticoid activation of chromogranin A gene expression. Identification and characterization of a novel glucocorticoid response element. Journal of Clinical Investigation 94, 2357-2368.
22. Peracchi, M., Gebbia, C., Basilisco, G., et al. (2005) Plasma chromogranin A in patients with autoimmune chronic atrophic gastritis, enterochromaffin-like cell lesions and gastric carcinoids. European Journal of Endocrinology 152, 443-448.
23. Sanduleanu, S., De Bruine, A., Stridsberg, M., et al. (2001) Serum chromogranin A as a screening test for gastric enterochromaffin-like cell hyperplasia during acid-suppressive therapy. European Journal of Clinical Investigation 31, 802-811.